• Read more about Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

NEW YORK, NY, April 8, 2022 – Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI® (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

• Read more about Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL® (Quinapril HCl) Due to N-Nitroso-Quinapril Content

FOR IMMEDIATE RELEASE - NEW YORK, NY., April 22,2022.

Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine, N-nitroso-quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. 

• Read more about Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age

NEW YORK and MAINZ, GERMANY, APRIL 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as children ages 5 through <12). 

• Read more about Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy

-- Regulatory authorities in United Kingdom, Canada, Taiwan, Spain and Belgium approve re-start of global Phase 3 CIFFREO study; additional reviews ongoing -- 

• Read more about Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use

NEW YORK, April 29, 2022 -- Pfizer Inc. (NYSE: PFE) today shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for post-exposure prophylactic use.

• Read more about Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022

NEW YORK, NY, May 4, 2022 – Pfizer Inc. (NYSE:PFE) announced today the presentation of real-world evidence demonstrating an associated benefit for patients treated with IBRANCE® (palbociclib) in combination with an aromatase inhibitor (AI), as compared to AI alone, in the first-line setting, at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 Congress.

• Read more about Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission

NEW YORK AND MAINZ, GERMANY, May 13, 2022 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced they have reached an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Pfizer-BioNTech COVID-19 Vaccine.

• Read more about Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development 

•    Effective August 1, Annaliesa Anderson will succeed Kathrin Jansen, who previously announced her retirement from Pfizer

NEW YORK, June 1, 2022 — Pfizer Inc. (NYSE: PFE) today announced that Annaliesa Anderson, Ph.D., has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Jansen, Ph.D., who will be retiring from Pfizer. 

• Read more about Meet The People Of PGS: Vanessa

Through the “People of PGS” series, we continue to spotlight the names and faces behind the great work we do in PGS. Next up is Vanessa, Site Leader at Meridian in St. Louis, who also has competed on Team USA’s Dragon Boat Racing team!

• Read more about Celebrating Our Veterans: A Salute to Their Service

It takes great bravery and honor to serve in the U.S. Military. At Pfizer, we are thankful to all veterans for their patriotism, their selflessness and their sacrifice. And, we are proud to call many men and women who have served in the armed forces Pfizer colleagues. We salute their service and invite you to read their stories.